Your browser doesn't support javascript.
loading
Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy.
Yamashita, Satoshi; Hattori, Naoko; Fujii, Satoshi; Yamaguchi, Takeshi; Takahashi, Masato; Hozumi, Yasuo; Kogawa, Takahiro; El-Omar, Omar; Liu, Yu-Yu; Arai, Nobuaki; Mori, Akiko; Higashimoto, Hiroko; Ushijima, Toshikazu; Mukai, Hirofumi.
Afiliação
  • Yamashita S; Division of Epigenomics, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
  • Hattori N; Division of Epigenomics, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
  • Fujii S; Division of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
  • Yamaguchi T; Department of Medical Oncology, Musashino Red Cross Hospital, 1-26-1, Kyonan, Musashino, Tokyo, 180-8610, Japan.
  • Takahashi M; Department of Breast Surgery, Hokkaido Cancer Center, National Hospital Organization, Kikusui 4-2, Shiroishi-Ku, Sapporo, 003-0806, Japan.
  • Hozumi Y; Department of Breast and Endocrine Surgery, Ibaraki Clinical Education and Training Center, Faculty of Medicine, Tsukuba University, Tsukuba, Japan.
  • Kogawa T; Department of Breast Surgery, Ibaraki Prefectural Central Hospital, 6528 Koibuchi, Kasama, Ibaraki, 309-1793, Japan.
  • El-Omar O; Department of Breast and Medical Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
  • Liu YY; Division of Epigenomics, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
  • Arai N; Division of Epigenomics, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
  • Mori A; Division of Epigenomics, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
  • Higashimoto H; H.U. Group Innovative Cancer Laboratory, H.U. Group Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
  • Ushijima T; H.U. Group Innovative Cancer Laboratory, H.U. Group Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
  • Mukai H; Division of Epigenomics, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. tushijim@ncc.go.jp.
Sci Rep ; 10(1): 15530, 2020 09 23.
Article em En | MEDLINE | ID: mdl-32968149
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Biomarcadores Tumorais / Receptor ErbB-2 / Proteína Multifuncional do Peroxissomo-2 / Antineoplásicos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Sci Rep Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Biomarcadores Tumorais / Receptor ErbB-2 / Proteína Multifuncional do Peroxissomo-2 / Antineoplásicos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Sci Rep Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Japão